Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Attracting a strong board

    How biotechs can make boards more attractive to top-tier candidates

    How biotechs can compete for board candidates who can meet the tests of independence and experience.

    Published on 4/25/2016
  • Figure: Money Raised in 2016

    Saved by a SNP Money Raised in 2016 Last week, the biotech industry raised $255 million, bringing to $10.8 billion the total raised year-to-date. In 2015, a total of $110.6 billion was raised, including $56.6 …

    Published on 4/25/2016
  • Table: Earnings on deck

    Saved by a SNP Earnings on deck At least 29 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 4Q; (B) Baxalta Inc. (NYSE:BXLT), which spun out of Baxter International Inc. (NYSE:BAX) last …

    Published on 4/25/2016
  • LPs choose Europe

    Why Charles River, Knight Therapeutics invested in Forbion's third fund

    Ebb & Flow LPs choose Europe Charles River Laboratories International Inc. (NYSE:CRL) and Knight Therapeutics Inc. (TSX:GUD) invested in Forbion Capital Partner's third life sciences fund to gain access to the firm…

    Published on 4/25/2016
  • Saved by a SNP

    Why DalCor's VCs are willing to bet on a CETP inhibitor

    Ebb & Flow Ebb & Flow Saved by a SNP Figure: Money Raised in 2016 Table: Earnings on deck At a time when venture dollars for cardiovascular companies are dwindling, DalCor Pharma U.K. Ltd. found a syndicate …

    Published on 4/25/2016
  • Targeting pharma

    Why Second Genome courted pharma VCs in its series B

    Ebb & Flow Targeting pharma Second Genome Inc. was looking for more than money in the $42.6 million series B round announced last week. The microbiome company also wanted to tap into pharma expertise that can help …

    Published on 4/25/2016
  • Figure: Money Raised in 2016

    Highline's hunter Money Raised in 2016 Last week, the biotech industry raised $334 million, bringing to $10.4 billion the total raised year-to-date. In 2015, a total of $110.6 billion was raised, including $56.6 …

    Published on 4/18/2016
  • Table: Earnings on deck

    Highline's hunter Earnings on deck At least six biotechs and pharmas are expected to report earnings this week. Company Date Pre/post mkt 1Q16 EPS est 1Q15 EPS Expected chg Johnson & Johnson (NYSE:JNJ) 4/…

    Published on 4/18/2016
  • Double-dipping

    How rumored Relypsa takeout could add to 5AM's returns

    Finance Double-dipping If takeout rumors about Relypsa Inc. (NASDAQ:RLYP) come true, 5AM Ventures is well positioned to improve upon the returns it has already achieved on the second of two lucrative sibling …

    Published on 4/18/2016
  • Highline's hunter

    How Versant's Highline incubator will fully bake its NYC newcos

    Ebb & Flow Ebb & Flow Highline's hunter Figure: Money Raised in 2016 Table: Earnings on deck Now that Versant Ventures' Highline Therapeutics has hired a veteran drug hunter and secured lab space in New York …

    Published on 4/18/2016
  • Sickle syndicate

    Why Cydan's backers joined firm in its second rare disease spinout

    Finance Sickle syndicate Orphan drug accelerator Cydan Development Inc. gathered enough preclinical data to convince its investor syndicate that sickle cell candidate IMR-687 is an asset worth building a company …

    Published on 4/18/2016
  • Monetizing M&A

    How Sosei monetized its acquisition of Heptares

    Ebb & Flow Monetizing M&A In just over a year, Sosei Group Corp. (Tokyo:4565) has nearly got back the $180 million in upfront cash it shelled out to buy Heptares Therapeutics Ltd. based on upfront payments and …

    Published on 4/11/2016
  • Figure: Money Raised in 2016

    Invest, not ingest Money Raised in 2016 Last week, the biotech industry raised $1,578 million, bringing to $9.9 billion the total raised year-to-date. In 2015, a total of $110.6 billion was raised, including $56.6…

    Published on 4/11/2016
  • Merger mania

    Why a scuttled mega-merger is driving biotech indices

    Ebb & Flow Merger mania The unraveling of the merger between Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) has some generalist investors betting bid prices will get more competitive as the two giants hunt for …

    Published on 4/11/2016
  • Invest, not ingest

    Why corporate VCs' parents rarely buy their portfolio companies

    Ebb & Flow Ebb & Flow Invest, not ingest Figure: Money Raised in 2016 There are myriad reasons for pharma and big biotech to make investments in fledgling companies through corporate venture arms, but data …

    Published on 4/11/2016
  • Table: 2Q milestones

    Ample opportunity 2Q milestones Selected products with clinical or regulatory milestones expected in 2Q16. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone Ablynx N.V.…

    Published on 4/4/2016
  • None shall pass

    Biotech winners, losers in 1Q16

    None of the market cap bands finished 1Q16 in positive territory.

    Published on 4/4/2016
  • Figure: Money Raised in 2016

    Frazier's GAIN Money Raised in 2016 Last week, the biotech industry raised $411 million, bringing to $8.3 billion the total raised year-to-date. In 2015, a total of $110.5 billion was raised, including $56.6 …

    Published on 4/4/2016
  • Figure: Among the bulls

    Fundamental reset Among the bulls The most recent biotech bull run, which followed the 2008-09 financial crisis, was the longest (333 weeks) and best performing (+543%) of the last five bull markets. Because of …

    Published on 4/4/2016
  • Figure: Biotech fund flows

    Fundamental reset Biotech fund flows Biotech funds saw net outflows of $3.2 billion in 1Q16, although there were signs of life in the quarter's final month. In 1Q15, net inflows were $4.1 billion. The March fund …

    Published on 4/4/2016
  • Table: Follow-on performance

    Fundamental reset Follow-on performance Follow-on activity tailed off in the last two months of the quarter, with about half of the 1Q offerings closing in February and March. For the quarter, $1.8 billion was …

    Published on 4/4/2016
  • Table: IPO performance

    Fundamental reset IPO performance While the number of IPOs dropped off last quarter, the group of newly public companies managed to post a median gain of 18%, led by a 149% rise in the market value of Korean …

    Published on 4/4/2016
  • Table: IPO queue

    Fundamental reset IPO queue At least seven companies have announced plans to go public since the start of 1Q16, bringing the IPO queue to at least 23. Unless noted, companies are seeking to list on NASDAQ. Filings…

    Published on 4/4/2016
  • Fundamental reset

    How biotech companies, bankers and buysiders will adjust to a new base in 2Q16

    With a floor nearly established and sector fundamentals unchanged, bio-bankers and buysiders agree it's a good time to put money to work.

    Published on 4/4/2016
  • Frazier's GAIN

    How GAIN Act, management teams led Frazier to back two big antibiotic A rounds

    Finance Ebb & Flow Frazier's GAIN Figure: Money Raised in 2016 The benefits of the Generating Antibiotic Incentives Now Act, coupled with the ability to back repeat entrepreneurs, prompted Frazier Healthcare …

    Published on 4/4/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993